Lorlatinib Market Analysis By Indication (Non-Small Cell Lung Cancer (NSCLC), Other Cancers), By Distribution Channel (Hospitals, Retail Pharmacies, Online Pharmacies) and by Region: Global Forecast, 2024 - 2034.
- PUBLISHED ON
- 2024-08-13
- NO OF PAGES
- 290
- CATEGORY
- Healthcare & Life Sciences
Market Overview
The Lorlatinib market is predicted to
develop at a compound annual growth rate (CAGR) of xx from
2024 to 2034, when it is projected to reach USD xx Billion, based on an average
growth pattern. The market is estimated to reach a value of USD xx Billion in
2024.
SOURCE: We Market Research
Lorlatinib, also
known as Lorbrena, is a tyrosine kinase inhibitor used to treat ALK-positive
non-small cell lung cancer (NSCLC) after previous therapies have failed. It
acts by targeting and inhibiting the ALK and ROS1 proteins, which stimulate
cancer cell proliferation. Lorlatinib, when administered orally in tablet form,
is known to treat adverse effects such as diarrhea, nausea, and edema. It is
FDA-approved for individuals with advanced or metastatic ALK-positive NSCLC.
The medicine is accessible in several regions and is given by oncologists to
improve outcomes in patients with this specific cancer type.
The global Lorlatinib market is expanding due to an increase in incidences of non-small cell lung cancer (NSCLC) with ALK mutations, which drives need for targeted treatments. Advances in oncology research and increased awareness lead to better diagnosis and treatment choices. Government funding and growing healthcare costs improve access to advanced therapies. Ongoing clinical trials and a robust pipeline of related medications increase commercial potential. Improved patient access through financial support and improved infrastructure also contribute to market growth, positioning Lorlatinib as a significant participant in the changing cancer treatment landscape.
Market Scope
|
Report Attributes |
Description |
|
Market Size in 2024 |
USD xx Billion |
|
Market
Forecast in 2034 |
USD xx Billion |
|
CAGR % 2024-2034 |
xx% |
|
Base
Year |
2023 |
|
Historic Data |
2016-2022 |
|
Forecast
Period |
2024-2034 |
|
Report USP
|
Production,
Consumption, company share, company heatmap, company production capacity,
growth factors and more |
|
Segments
Covered |
By
Indication, By Distribution Channel and By Region |
|
Regional Scope |
North America,
Europe, APAC, South America and Middle East and Africa |
|
Country
Scope |
U.S.; Canada;
U.K.; Germany; France; Italy; Spain; Benelux; Nordic Countries; Russia;
China; India; Japan; South Korea; Australia; Indonesia; Thailand; Mexico;
Brazil; Argentina; Saudi Arabia; UAE; Egypt; South Africa; Nigeria |
Lorlatinib Industry: Dynamics & Restrains
Market opportunity:
We Market
Research: Lorlatinib Dashboard
Our marketing platform offers a comprehensive dashboard that provides clients with valuable insights into market trends over the years. Included below is a sample image of our dashboard, and specific PDF logins will be furnished to grant access to this insightful tool.
Lorlatinib Segmentation
Market- By Indication Analysis
By Indication, the Lorlatinib Market is Categories into Non-Small Cell Lung Cancer (NSCLC), Other Cancers. The Non-Small Cell Lung Cancer (NSCLC) segment accounts for the largest share of around 88% in 2024.
Lorlatinib's success in NSCLC is driven by
the increased incidence of this cancer type and its specific effectiveness
against ALK-positive NSCLC, which improves patient outcomes and promotes demand
for tailored, advanced treatments in this market.
The
following segments are part of an in-depth analysis of the global Lorlatinib
market:
|
Market
Segments |
|
|
By
Distribution Channel |